

## Preventive Effect of hydroalcoholic extract of Silybum marianum and fumaria vaillantii in atherosclerosis


Madani H.\*, Talebolhosseiny M., Asgari S., Mahzooni P., Razban E.

Faculty of Science, Isfahan University, Department of Biology

Received: 2006/8/5, Accepted: 2007/4/18

Objectives: Atherosclerosis is a disease of the vascular system that produces a gradual deposition of lipids in large and medium arteries. This disease is the most common cause of death in the world. The increase in cholesterol is an important factor in development of atherosclerosis. Epidemiological studies have shown significant and positive affinity between total cholesterol and LDL cholesterol of serum by the formation of these diseases, but this affinity is negative about HDL cholesterol. It is reported that plant extracts contain flavonoids which are effective for the reduction of serum cholesterol. Silybum marianum of Asteracea family and fumaria vaillantii of fumariacea family contain flavonoid compounds. In this study we have evaluated the effect of hydroalcoholic extract of these plants on the level of serum cholesterol. Methods: 20 male rabbits were randomly divided in four experimental groups. Through 45 days, 4 groups were fed with standard food, hypercholesterolic food, hypercholesterolic food with Silybum marianum extract and hypercolesterolic food with fumaria vaillantii extract respectively. Then total cholesterol (TC), LDL cholesterol, HDL cholesterol and triglycerides (TG) were measured before and after experimental periods of 1 and 2 months of. The aorta was removed for assessment of atherosclerosis plaques. Results: The results indicate that in the third and fourth group the extracts of both plants reduce the amount of TC, LDL and TG but the amount of HDL augment. Conclusion: Therefore the extracts of Silybum marianum and fumaria vaillantii can be effective inhibited the development of atherosclerosis.

Key words: Atherosclerosis, Hypercolesterol, flavonoid, Silybum marianum, fumaria vaillantii.



\*Corresponding Author: Dr Hossein Madani, Assistant Professor, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tel: 0311-7932462; Fax: 0311-7932456; E-mail: h.madani@biol.ui.ac.ir

www.SID.ir

.( ) ) .( ) .(% (Asteracea) Silybum marianum % .( ) VLDL LDL .( ) HDL .( ) C25H22O10 Fumariacae Fumaria vaillantii loisei .( ) .( ) .( )

www.SID.ir

۳١

```
.(p<0.05)
              (p<0.05)
                                                           LDL
.(
              ) (p>0.05)
      LDL
                                                                           HDL
                                                                                             LDL
     2000
     1500
 TC (mg/dl)
                                                                                                                 VLDL
     1000
      500
                           (TC)
            mg/dl
                                                                                                                               .( )
     2000
     1500
 LDL (mg/dl)
     1000
      500
                      mg/dl
      800
TG (mg/dl)
      600
                                                                                                                                 SPSS
      400
      200
                                                                                   P < /
                                                                                                                                 Mean ± sd
                          (TG)
            mg/dl \\
                                                                                                                .(p>0.05)
                             VLDL
                                                                                                                          LDL
      .(p<0.05)
                                                                                                .(p<0.05)
```

VLDL

LDL

```
HDL
                                                                        VLDL
                                                                                                   .(p<0.05)
                                      .(
                                               ) (p<0.05)
                                                                                                         .(p>0.05)
                                                                  (Ip/Bu) 100
50
                    .(
.(
           )
                                                                                                VLDL
                                                                                  mg/dl
                                              .(
                                                                                                2
                                                                                                 HDL
                                                                                     mg/dl
                                                                 HDL
                                                                                                     HDL
                                                                    HDL
                                                                                .(p<0.05)
                                                                        .(p<0.05)
```

٣٣



www.SID.ir

( In vitro LDL , ( LDL .

.( ) .( ) :

## **6- Refrences**

- Braunwald E. Heart disease. Saunders company, Philadelphia, Pensylvania., 1997, Vol 3: 1625.
- Braunwald E. Heart disease. A tex book of cardiovascular medicine. 6<sup>th</sup> Ed. Saunders company, 2001, Sydney, Torento, 2297.
- company, 2001, Sydney, Torento, 2297.
   Moarreaf A.R. Risk factors modification of coronary artery disease. Shiraz E-medical journal., 2004, 5:1-7.
- 4. Lankin V.Z., Tikhaze A., Kukharchuk V. and Belenkove Y. Antioxidant decrease the intensification of LDL in-vivo proxidation during therapy with statins. Molecular and cellular biochemistry., 2003, 249: 126-140.
- Patrick L. and Uzick M. cardiovascular disease: creactive protein and the inflammatory disease paradigm. Alternative medicine review., 2001, 6: 248-271.
- Leng-Peschlow E. and Madause A. G. Properties and medical use of flavonolignans from silybum marianum. Phytotherapy Res., 1996, 1: 25-26.
- 7.Skottova N., Krecman V., Vana P., Chemla Z., Ulrichova J. and Simanek V. Effect of silymarin and silibin-phosphatidyl choline complex on plasma and lipoprotein cholesterol and oxidation of LDL in rats fed on high cholesterol diet with currant oil. Acta. Univ. Palacki. Olomuc., Fac. Med., 2000, 144: 55-57.
- 8. Quaglia, M. G., Bossu, E., Donati, E., Mazzanti, G. And Brandt, A. 1999. Determination of silymarin in the extract from the dried silybum marianum fruits by high performance liquid chromatography and capillary electrophoresis. J. of pharmaceutical and Biomedical Analysis, 19: 435-442.
- Sousek J., Guedon D. Adam T., Bochorakova H., Taborska E., Valka I. and Simanek V. Alkaloids and organic acids content of eight fumaria speciese. Phytochemical Analysis., 1998, 10: 6-11.

10.Aherne S. A. and O'Brien N. M. Dietary flavonols, chemistry, food content, and metabolism. Nutrition., 2002, 18: 75-81.

α

- 11. Schonfeld, J. V., Weisbrod, B. And Muller, M. K. Silibinin
  aplant extract with antioxidant and membrane stabilizing preperties. Cell. Mol. Lif. Sci., 1997, 53: 917-920.
- 12. Krecmane V., Skottova N., Walterova D., Ulrichova J. and Simanek V. Silymarin inhibits the development of diet-induced hypercholesterolemia in rats. Planta Medica1., 1998, 64: 138-142.
- 13. Chekanov V. Low frequency electrical impulses reduce atherosclerosis in cholesterol fed rabbits. Medical Science., 2003, 9: 302-309.
- 14.Paganga G., Miller N. and Rice-Evans C.A. The polyphenolic content of fruit and vegetable and their antioxidant. Free Radic. Res., 1999, 30(2): 153-162.
- Davis S.R., Murkies A. L. and Wilox G. Phytostrogens in clinical practice. Integrative Medicine., 1998, 1: 27-34.
- 16.Skottova N. and Kreeman V. Silymarin as a potential hypercholesterolemic drug. Physiol. Res., 1998, 47: 1-7.
- Skottova N. and Krecman V.Dietary silymarin improves removal of low density lipoproteins by the perfused rat liver. Acta Uni. Palaki. Olomuc., Fac. Med., 1998, 141: 39-40.
- 18. Seidlova-Wuttke D., Christoffel V., Jarry H. and Wuttke W. Silymarin is a selective estrogen receptor β (ERβ) agonist and has estrogenic effects in metaphysic of femur but no or antiestrogenic effets in the ulterus of ovariectomized (OVX) rats. Sterid Biochemistry&Molecular Biology., 2003, 86: 179-188.
- Sener S. Recent result in the search for bioactive compounds from Turkish medicinal plants. Pur & Appl.Chem., 1994, 66: 2295-2298.
- Hakborne J. B. The flavonoids. 1<sup>th</sup> Ed. London. Chapman & Hall., 1986, 676.